NEDD4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17141990	1.00	1/20
SCHEMBL17141994	1.00	1/20
SCHEMBL18996019	0.86	1/20
SCHEMBL17141988	0.83	1/20
SCHEMBL17142016	0.82	1/20
SCHEMBL18996018	0.81	1/20
SCHEMBL17141933	0.79	1/20
SCHEMBL17141961	0.78	1/20
SCHEMBL17141981	0.76	1/20
SCHEMBL17142002	0.76	1/20
SCHEMBL17142014	0.76	1/20
SCHEMBL17141916	0.72	1/20
SCHEMBL17141919	0.71	1/20
SCHEMBL17141953	0.71	1/20
SCHEMBL17141921	0.71	1/20
SCHEMBL17141992	0.71	1/20
SCHEMBL17141923	0.70	1/20
SCHEMBL19001519	0.69	1/20
SCHEMBL17141978	0.69	1/20
SCHEMBL17142013	0.69	1/20

Clinical trials — most relevant to NEDD4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
Angiotensin 1-7 as a Therapy in the Treatment of COVID-19	PHASE2	UNKNOWN
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment	PHASE2	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults	nan	NOT_YET_RECRUITING
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease	nan	UNKNOWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
The Activation of Hippo Pathway in Nasal Polyps	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NEDD4 binder may also engage these)

Protein	Name	Similarity
Q90ZS6	—	0.997	Q90ZS6 →
P46200	—	0.997	P46200 →
A0A2K1J5A5	—	0.997	A0A2K1J5A5 →
Q3YC04	—	0.997	Q3YC04 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.997	landscape →
Q4JM28	—	0.996	Q4JM28 →
Q9SB51	—	0.996	Q9SB51 →
Q8VII8	—	0.996	Q8VII8 →
P70284	—	0.996	P70284 →
Q6PEV8	—	0.995	Q6PEV8 →
Q15154	—	0.995	Q15154 →
Q949U2	—	0.995	Q949U2 →
Q90655	—	0.995	Q90655 →
P22199	—	0.995	P22199 →
Q29131	—	0.995	Q29131 →
Q1LXZ9	—	0.994	Q1LXZ9 →
Q8TFG6	—	0.994	Q8TFG6 →
Q6DFV3	—	0.994	Q6DFV3 →
P49844	—	0.994	P49844 →
Q865B7	—	0.994	Q865B7 →
P10244	—	0.994	P10244 →
Q9D2H8	—	0.994	Q9D2H8 →
Q10668	—	0.994	Q10668 →
B3DHS1	—	0.994	B3DHS1 →
Q8C0P0	—	0.994	Q8C0P0 →
PEAK1	Inactive tyrosine-protein kinase PEAK1	0.993	landscape →
Q9BYI3	—	0.993	Q9BYI3 →
Q5R8X7	—	0.993	Q5R8X7 →
Q5SPL2	—	0.993	Q5SPL2 →
Q2PFD7	—	0.993	Q2PFD7 →